Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 4.4% – Here’s Why

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) was down 4.4% during mid-day trading on Monday . The company traded as low as $32.50 and last traded at $32.3350. Approximately 5,424 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 211,740 shares. The stock had previously closed at $33.84.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 target price for the company. JonesTrading assumed coverage on shares of Sensei Biotherapeutics in a report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price objective on the stock. Wall Street Zen upgraded shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Raymond James Financial started coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 target price for the company. Finally, Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Sensei Biotherapeutics Trading Down 5.7%

The firm has a market cap of $824.81 million, a P/E ratio of -0.23 and a beta of -0.25. The business has a 50-day simple moving average of $28.53.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. Equities analysts forecast that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In related news, CFO Brian C. Stephenson purchased 9,391 shares of Sensei Biotherapeutics stock in a transaction dated Wednesday, June 24th. The stock was bought at an average cost of $26.13 per share, with a total value of $245,386.83. Following the purchase, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. The trade was a 53.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of Sensei Biotherapeutics stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 49,494 shares of company stock valued at $1,188,822 in the last quarter. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FTH. Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after purchasing an additional 1,100 shares during the period. Bank of America Corp DE increased its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics in the 1st quarter worth $4,188,000. Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics in the 2nd quarter worth $3,610,000. Finally, Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics in the first quarter valued at $22,758,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.